Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing

Minqiu Lu; Yin Wu; Wen Gao; Ying Tian; Guorong Wang; Aijun Liu; Wenming Chen

doi:10.3389/fgene.2021.625019

Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing

Front Genet. 2021 May 24:12:625019. doi: 10.3389/fgene.2021.625019. eCollection 2021.

Authors

Minqiu Lu^{1

2}, Yin Wu¹, Wen Gao¹, Ying Tian¹, Guorong Wang¹, Aijun Liu¹, Wenming Chen¹

Affiliations

¹ Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
² Department of Hematology, Beijing Jishuitan Hospital, Fourth Medical College of Peking University, Beijing, China.

Abstract

This study aimed to explore the potential effects of novel non-coding ribose nucleic acids (ncRNAs) in patients with multiple myeloma (MM). The gene expression profile of plasma cells was used for sequence analysis to explore the expression pattern of ncRNAs in MM. The expression patterns of non-coding RNAs in MM were analyzed by RNA sequencing (whole-transcriptome-specific RNA sequencing). Next, the expression of the selected ncRNAs was verified by quantitative real-time polymerase chain reaction. Further, the lncRNA-associated competitive endogenous RNA network in MM was elucidated using deep RNA-seq. Differentially expressed (DE) ncRNAs were significantly regulated in patients with MM. DE target lncRNAs were analyzed by cis and trans targeting prediction. Two new lncRNAs were shown to be related to MM oncogenes. MSTRG.155519 played a carcinogenic role in myeloma by targeting CEACAM1; MSTRG.13132 was related to FAM46C. Finally, the network of lncRNA-mRNA-miRNA in MM was constructed in this study. The expression of non-coding RNAs through sequence and functional analyses might be helpful for further studies on the pathogenesis of MM and the development of new MM-targeted therapy for non-coding RNAs.

Keywords: ceRNA; multiple myeloma; non-coding RNAs; oncogene; sequencing.